Plain-English translation of NCT07018596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the CellFX nsPFA Catheter System, a new technology that uses nanosecond pulsed electrical fields to treat paroxysmal atrial fibrillation—a condition where your heart beats irregularly and then returns to normal on its own. The study will enroll about 215 people with irregular heartbeat that hasn't responded well to medication, and researchers will follow them for at least 6 months after the procedure to see how safe and effective the treatment is.
Current medications don't work for everyone with atrial fibrillation, and some people can't tolerate their side effects. This trial is testing whether this new ablation technology offers a better option for people whose symptoms aren't controlled by drugs.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo an ablation procedure using the new CellFX catheter system, which involves threading a special catheter through blood vessels to reach your heart and treat the tissue causing irregular heartbeats. After the procedure, you will have follow-up visits and testing over at least 6 months so researchers can monitor how well the treatment works and check for any side effects.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Czechia
Sponsor
Pulse Biosciences, Inc.
Enrollment target
~215 participants
Started
April 2026
Primary completion
October 2026
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Micki Weisman
Pulse Biosciences, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.